Literature DB >> 25059587

Diagnosis and treatment of malignant pleural mesothelioma.

Francisco Rodríguez Panadero1.   

Abstract

There are three major challenges in the diagnosis of malignant pleural mesothelioma: mesothelioma must be distinguished from benign mesothelial hyperplasia; malignant mesothelioma (and its subtypes) must be distinguished from metastatic carcinoma; and invasion of structures adjacent to the pleura must be demonstrated. The basis for clarifying the first two aspects is determination of a panel of monoclonal antibodies with appropriate immunohistochemical evaluation performed by highly qualified experts. Clarification of the third aspect requires sufficiently abundant, deep biopsy material, for which thoracoscopy is the technique of choice. Video-assisted needle biopsy with real-time imaging can be of great assistance when there is diffuse nodal thickening and scant or absent effusion. Given the difficulties of reaching an early diagnosis, cure is not generally achieved with radical surgery (pleuropneumonectomy), so liberation of the tumor mass with pleurectomy/decortication combined with chemo- or radiation therapy (multimodal treatment) has been gaining followers in recent years. In cases in which surgery is not feasible, chemotherapy (a combination of pemetrexed and platinum-derived compounds, in most cases) with pleurodesis or a tunneled pleural drainage catheter, if control of pleural effusion is required, can be considered. Radiation therapy is reserved for treatment of pain associated with infiltration of the chest wall or any other neighboring structure. In any case, comprehensive support treatment for pain control in specialist units is essential: this acquires particular significance in this type of malignancy.
Copyright © 2014 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Biomarcadores; Biomarkers; Derrame pleural maligno; Malignant pleural effusion; Malignant pleural mesothelioma; Mesotelioma pleural maligno; Thoracoscopy; Toracoscopia

Mesh:

Year:  2014        PMID: 25059587     DOI: 10.1016/j.arbres.2014.06.005

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  7 in total

Review 1.  Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.

Authors:  Weiquan Zhang; Xinshu Wu; Licun Wu; Weidong Zhang; Xiaogang Zhao
Journal:  Ann Transl Med       Date:  2015-08

2.  A case of severe arthralgia with malignant mesothelioma-associated hypertrophic osteoarthropathy.

Authors:  Hideaki Yamakawa; Akimasa Sekine; Terufumi Kato; Yumie Yamanaka; Eri Hagiwara; Shigeaki Umeda; Takashi Ogura
Journal:  Clin Case Rep       Date:  2016-10-05

Review 3.  CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Authors:  Lourdes Cortes-Dericks; Ralph Alexander Schmid
Journal:  Respir Res       Date:  2017-04-12

4.  A 75 year old male with recurrent unilateral pleural effusion and positive ANA.

Authors:  Tanner Wallen; Nikhil Jagan; Mridula Krishnan; Zachary Depew
Journal:  Respir Med Case Rep       Date:  2019-02-22

5.  Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.

Authors:  Li-Li Xu; Yuan Yang; Zhen Wang; Xiao-Juan Wang; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  BMC Pulm Med       Date:  2018-04-03       Impact factor: 3.317

6.  Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review.

Authors:  Nadia Sattar; Richard Durrance; Ahmed Khan; Nilesh Patel; Maximo Mora; Artur Shalonov
Journal:  Respir Med Case Rep       Date:  2018-02-24

Review 7.  Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.

Authors:  Sophie Rovers; Annelies Janssens; Jo Raskin; Patrick Pauwels; Jan P van Meerbeeck; Evelien Smits; Elly Marcq
Journal:  Biomedicines       Date:  2022-03-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.